Important considerations in the management of Graves' disease in pregnant women

Okosieme, Onyebuchi E. and Lazarus, John Henry 2015. Important considerations in the management of Graves' disease in pregnant women. Expert Review of Clinical Immunology 11 (8) , pp. 947-957. 10.1586/1744666X.2015.1054375

Full text not available from this repository.

Abstract

Graves’ disease is an autoimmune disorder in which autoantibodies to the thyroid-stimulating hormone receptor cause hyperthyroidism through unregulated stimulation of the thyroid-stimulating hormone receptor. Effective management of Graves’ disease in pregnancy must address the competing fetal and maternal priorities of controlling hyperthyroidism in the mother on the one hand, and on the other, minimizing the impact of maternal disease and antithyroid drugs on the well-being of the fetus. Optimal strategies for achieving this intricate balance are currently a source of continued debate among thyroid experts and studies in recent decades are now providing greater clarity into the risk posed to the unborn baby by the combination of biochemical, immunological and pharmacological hazards arising from Graves’ disease and its therapy. This review summarizes the current best practice and highlights important considerations and areas of uncertainty in the management of Graves’ disease in pregnant women.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Medicine
Subjects:	R Medicine > R Medicine (General) R Medicine > RG Gynecology and obstetrics
Uncontrolled Keywords:	antithyroid drugs, Graves’ disease, hyperthyroidism, pregnancy, TSH receptor antibody
Publisher:	Taylor & Francis Group
ISSN:	1744-666X
Last Modified:	11 Jun 2019 12:02
URI:	https://orca.cardiff.ac.uk/id/eprint/84754

Citation Data

Cited 12 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item